146 related articles for article (PubMed ID: 28642461)
1. The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells.
Barnett D; Liu Y; Partyka K; Huang Y; Tang H; Hostetter G; Brand RE; Singhi AD; Drake RR; Haab BB
Sci Rep; 2017 Jun; 7(1):4020. PubMed ID: 28642461
[TBL] [Abstract][Full Text] [Related]
2. Imaging Mass Spectrometry and Lectin Analysis of N-Linked Glycans in Carbohydrate Antigen-Defined Pancreatic Cancer Tissues.
McDowell CT; Klamer Z; Hall J; West CA; Wisniewski L; Powers TW; Angel PM; Mehta AS; Lewin DN; Haab BB; Drake RR
Mol Cell Proteomics; 2021; 20():100012. PubMed ID: 33581409
[TBL] [Abstract][Full Text] [Related]
3. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
4. Detection of Chemotherapy-resistant Pancreatic Cancer Using a Glycan Biomarker, sTRA.
Gao C; Wisniewski L; Liu Y; Staal B; Beddows I; Plenker D; Aldakkak M; Hall J; Barnett D; Gouda MK; Allen P; Drake R; Zureikat A; Huang Y; Evans D; Singhi A; Brand RE; Tuveson DA; Tsai S; Haab BB
Clin Cancer Res; 2021 Jan; 27(1):226-236. PubMed ID: 33093149
[TBL] [Abstract][Full Text] [Related]
5. Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.
Huang T; Jiang SW; Qin L; Senkowski C; Lyle C; Terry K; Brower S; Chen H; Glasgow W; Wei Y; Li J
Int J Mol Sci; 2015 Jan; 16(2):2956-70. PubMed ID: 25642754
[TBL] [Abstract][Full Text] [Related]
6. High serum levels of DUPAN2 antigen and CA19-9 in pancreatic cancer: correlation with immunocytochemical localization of antigens in cancer cells.
Suzuki Y; Ichihara T; Nakao A; Sakamoto J; Takagi H; Nagura H
Hepatogastroenterology; 1988 Jun; 35(3):128-35. PubMed ID: 3042577
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2.
Kawa S; Kato M; Oguchi H; Hsue GL; Kobayashi T; Koiwai T; Tokoo M; Furuta S; Ichikawa T; Kanai M
Scand J Gastroenterol; 1992 Aug; 27(8):635-43. PubMed ID: 1359630
[TBL] [Abstract][Full Text] [Related]
8. Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.
Tang H; Singh S; Partyka K; Kletter D; Hsueh P; Yadav J; Ensink E; Bern M; Hostetter G; Hartman D; Huang Y; Brand RE; Haab BB
Mol Cell Proteomics; 2015 May; 14(5):1323-33. PubMed ID: 25733690
[TBL] [Abstract][Full Text] [Related]
9. [Clinical usefulness of tumor markers associated with pancreatic cancer].
Watanabe H; Kawakami H; Yamakawa O; Satomura Y; Ohta H; Motoo Y; Okai T; Sawabu N
Rinsho Byori; 1994 Feb; 42(2):127-38. PubMed ID: 7908065
[TBL] [Abstract][Full Text] [Related]
10. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter.
Luo G; Jin K; Deng S; Cheng H; Fan Z; Gong Y; Qian Y; Huang Q; Ni Q; Liu C; Yu X
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188409. PubMed ID: 32827580
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer.
Kobayashi T; Kawa S; Tokoo M; Oguchi H; Kiyosawa K; Furuta S; Kanai M; Homma T
Scand J Gastroenterol; 1991 Jul; 26(7):787-97. PubMed ID: 1896821
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of RCAS1 as serum tumor marker for pancreatic cancer].
Yang YC; Zhao YP; Liao Q; Zhang TP; Hu Y; Dai MH
Zhonghua Wai Ke Za Zhi; 2009 Jul; 47(13):999-1001. PubMed ID: 19957811
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of glycan biomarker clusters as an indicator of recurrence in pancreatic cancer.
Wisniewski L; Braak S; Klamer Z; Gao C; Shi C; Allen P; Haab BB
Front Oncol; 2023; 13():1135405. PubMed ID: 37124496
[TBL] [Abstract][Full Text] [Related]
15. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer.
Banfi G; Zerbi A; Pastori S; Parolini D; Di Carlo V; Bonini P
Clin Chem; 1993 Mar; 39(3):420-3. PubMed ID: 8448851
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical studies on the localization of cancer associated antigens DU-PAN-2 and CA19-9 in carcinomas of the digestive tract.
Ohshio G; Ogawa K; Kudo H; Yamabe H; Nakashima Y; Kim YC; Endo K; Watanabe Y; Manabe T; Tobe T
J Gastroenterol Hepatol; 1990; 5(1):25-31. PubMed ID: 2103381
[TBL] [Abstract][Full Text] [Related]
17. Expression of various sialylated carbohydrate antigens in malignant and nonmalignant pancreatic tissues.
Satomura Y; Sawabu N; Takemori Y; Ohta H; Watanabe H; Okai T; Watanabe K; Matsuno H; Konishi F
Pancreas; 1991 Jul; 6(4):448-58. PubMed ID: 1678888
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of Glycan Biomarker Clusters as an Indicator of Recurrence in Pancreatic Cancer.
Wisniewski L; Braak S; Klamer Z; Gao C; Shi C; Allen P; Haab BB
bioRxiv; 2023 Jan; ():. PubMed ID: 36711795
[TBL] [Abstract][Full Text] [Related]
19. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.
Takeda S; Nakao A; Ichihara T; Suzuki Y; Nonami T; Harada A; Koshikawa T; Takagi H
Hepatogastroenterology; 1991 Apr; 38(2):143-8. PubMed ID: 1855772
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.
Kawa S; Oguchi H; Kobayashi T; Tokoo M; Furuta S; Kanai M; Homma T
Br J Cancer; 1991 Nov; 64(5):899-902. PubMed ID: 1931612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]